This document summarizes Greg Norden's presentation at the 2008 Citi Investment Research Global Healthcare Conference on May 21, 2008. It discusses Wyeth's financial guidance for 2008, performance in the first quarter of 2008, key product growth drivers, focus on driving international growth, pipeline of new products in development, and initiatives to sharpen focus and manage costs through Project Impact. The presentation outlines Wyeth's strategy to position itself for future growth through a diversified business, new product launches, global expansion opportunities, and a proven R&D pipeline.
Bayer reported Q3 2018 results and confirmed full year guidance. Key highlights included:
- Q3 sales of €9.9 billion, up 2% year-over-year on a currency and portfolio adjusted basis.
- EBITDA of €2.2 billion, down 18% due to currency effects and higher costs of goods sold.
- Integration of Monsanto is proceeding as planned and synergies are being realized.
- Net debt was further reduced to €36.5 billion at the end of Q3.
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020Bayer
The document summarizes Bayer's Q1 2020 earnings results and provides an outlook for 2020. Key highlights include:
- Q1 sales increased 6% to €12.8 billion driven by growth in Crop Science and Pharmaceuticals. EBITDA rose 10% to €4.4 billion.
- All business segments saw increased demand related to the COVID-19 pandemic. Crop Science had strong growth in insecticides and herbicides. Pharmaceuticals was led by Xarelto growth. Consumer Health saw elevated demand across categories.
- The outlook acknowledges COVID-19 uncertainty and focuses on maintaining operations, progressing the pipeline, continuing integration efforts, and realizing efficiency programs. Net debt was largely unchanged from year
Bayer reported financial results for FY/Q4 2017. Group sales increased 2% to €35.0 billion, while EBITDA before special items remained at the prior year level of €9.3 billion. Core EPS from continuing operations increased 1% to €6.74. Pharmaceuticals recorded higher sales and encouraging earnings growth. The Crop Science business was down against the prior year as expected due to measures in Brazil. Bayer expects to close the acquisition of Monsanto in Q2 2018 pending regulatory approval.
Werner Baumann, CEO of Bayer, summarized the company's Q1 2018 results. Sales were down 5% year-over-year due to currency effects, while core EPS rose slightly. The acquisition of Monsanto is pending regulatory approval, with two-thirds of approvals received so far. Guidance for full-year 2018 was confirmed, expecting low-single digit sales decline but mid-single digit growth adjusting for currency. Key growth products and segments like pharmaceuticals were up significantly.
Bayer reported its Q3 2019 results with continued growth across all divisions. Key highlights include:
- Group sales increased 5% to €9.8 billion driven by strong growth in Pharmaceuticals and Crop Science.
- EBITDA before special items grew 8% to €2.3 billion with margins up 30 basis points.
- Core EPS increased 6% to €1.16. Free cash flow grew 13% to €1.3 billion.
- Guidance for 2019 was confirmed with sales of ~€46 billion, EBITDA before special items of ~€12.2 billion, and core EPS of ~€6.80.
The document provides an investor conference call summary for Bayer's Q2 2021 results. It includes the following key points:
- Bayer increased its full-year 2021 guidance for sales, EBITDA margin, core EPS, and net financial debt due to strong first half performance.
- All business divisions (Crop Science, Pharmaceuticals, Consumer Health) contributed to sales growth in Q2 2021 and are expected to grow for the full year.
- EBITDA before special items was lower in Q2 2021 due to currency headwinds, but margins are expected to improve for the full year.
- Free cash flow was impacted by litigation settlement payouts of €0.9 billion
Bayer reported strong financial results for FY 2021 despite challenges from currency headwinds and inflation. Group sales increased 7% to €44.1 billion driven by growth across all divisions. Core EPS rose to €6.51. Bayer expects continued sales and earnings growth in 2022, forecasting sales of ~€46 billion and Core EPS of ~€7.00 at constant currencies. Key assumptions include mid-single digit growth in Crop Science and Consumer Health and low single digit growth in Pharmaceuticals.
Crop Science Summer Technology Showcase August 1, 2019Bayer
Keynote presentations by Werner Baumann, Liam Cond, Bob Reiter and Mike Stern at the Crop Science Summer Technology Showcase on August 1, 2019 in the Bayer Chesterfield Research Center, Missouri, U.S.A.
Bayer reported its FY/Q4 2019 results, achieving its guidance targets. Sales were €43.5 billion, EBITDA was €11.5 billion, and core EPS was €6.40. Each business division performed well, with Crop Science benefiting from integration synergies, Pharmaceuticals growing due to drugs like Xarelto and Eylea, and Consumer Health returning to peer growth. Bayer also progressed on portfolio measures, signing agreements to divest its Animal Health division and other smaller businesses. Looking ahead, Bayer provided guidance for 2020 of continued sales and earnings growth.
Bayer reported results for FY/Q4 2018. Group sales increased 3% to €39.6 billion, meeting guidance. EBITDA before special items rose 5% to €9.5 billion, also meeting forecast. Core EPS was €5.94, slightly above the narrowed guidance range. For 2019, Bayer expects sales of about €46 billion (16% growth including Monsanto acquisition), EBITDA before special items of around €12.2 billion (28% increase), and Core EPS of approximately €6.80 (14% growth). Key focus areas for 2019 include delivering operational targets, integrating Crop Science, executing efficiency programs, defending glyphosate litigation, and improving Consumer Health performance.
Bayer reported financial results for full-year and Q4 2020. Despite currency headwinds, the company achieved its updated guidance for sales, EBITDA margin, core EPS and free cash flow. For 2021, Bayer expects sales of €42-43 billion, an EBITDA margin of around 27%, and core EPS of €6.10-€6.30. However, currency effects are expected to reduce sales by around €2 billion and core EPS by around €0.50 compared to constant currencies. Free cash flow is guided to be negative €3-4 billion due to planned litigation settlements of around €8 billion.
Bayer reported its Q2 2018 results and provided an outlook for fiscal year 2018 including the impact of the Monsanto acquisition. Key points include:
- The Monsanto acquisition closed on June 7th and integration is underway.
- Q2 performance was on track to meet previous targets. Guidance now reflects Monsanto.
- Full year sales are expected to increase mid-single digits including Monsanto. EBITDA is forecast to rise high-single digits.
- Core EPS is projected to decrease high-single digits due to Monsanto seasonality and financing costs, but Monsanto is expected to be accretive in the first year.
- Net debt is estimated to reduce to around €37 billion by
The document summarizes Bayer's Q2 2019 earnings results. Key points include:
- Sales increased 21% to €11.5 billion (+1% at constant currencies) driven by the Monsanto acquisition.
- EBITDA before special items grew 25% to €2.9 billion with margins up 70 basis points.
- Core EPS increased 6% to €1.62.
- Free cash flow was €751 million, impacted by timing effects from the prior year period.
- Guidance for 2019 was confirmed despite ambitious targets.
Disclaimer
This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
- Bayer reported strong results for Q3 2016, with sales up 4% and core EPS up 6% compared to Q3 2015.
- Full year 2016 forecasts were raised, with core EPS growth now expected to be in the high single digits.
- Pharmaceuticals continues to perform well, with launch products sales up 28% and a raised outlook to over €16 billion for 2016.
- Crop Science sales were flat due to difficult market conditions, though the outlook remains for 2016 sales to be around €10 billion.
- The acquisition of Monsanto was agreed and integration plans are underway.
Bayer reported strong results for Q1 2019, with sales increasing 42.4% to €13.0 billion and EBITDA before special items improving 44.6% to €4.2 billion. All business segments performed well, with Crop Science sales up 6% driven by growth in Latin America and North America. Pharmaceuticals grew 5% led by 15% increases for Xarelto and Eylea. Consumer Health declined 1% due to competition in North America. Full-year 2019 guidance was confirmed.
- Bruker Corporation reported financial results for Q1 2016 with total revenue increasing 6.2% year-over-year to $375.4 million. Organic revenue growth was 5.6% excluding currency effects and M&A.
- Non-GAAP operating margin expanded 250 basis points to 12.6% due to increased operating leverage. Non-GAAP EPS grew 50% year-over-year.
- For full-year 2016, Bruker expects organic revenue growth of approximately 3% and non-GAAP operating margin expansion of approximately 100 basis points year-over-year. Guidance for non-GAAP EPS is $0.97 to $1.02.
- Bayer achieved record sales and earnings in FY2016, with sales up 3% and adjusted EBITDA up 10% despite difficult market conditions.
- Pharmaceuticals delivered substantial growth with key products up 29% and earnings up 14%.
- CropScience was successful in difficult markets, with earnings flat despite a 7% sales decline in Latin America.
- Consumer Health grew sales 4% with competition, while Animal Health grew 5% led by strong Seresto performance.
- Bayer forecasts further sales and earnings growth in FY2017 across segments and announced budgets of €4.8B for R&D and €2.5B for capital expenditures.
- The acquisition of Monsanto is
Marketing Asset Center - Enabling Consistency & Productivity Across Sales & M...rivetlogic
The Digital Marketing landscape continues to transform in the form of content marketing, big data, mobile marketing, and social media. All of this equates to an abundance of digital marketing assets – audio, video, images, documents, corporate communications, campaign assets, and more – which need to be effectively managed and distributed to various stakeholders – sales teams, employees, partners, customers, remote offices, and others.
The Marketing Asset Center provides a powerful and easy way for enterprises to manage and distribute all their digital marketing assets, resulting in increased marketing productivity, brand consistency, sales effectiveness, and revenue.
This document provides a brief tour around parts of Europe and Africa as seen from space at night, noting locations like the Iberian Peninsula, Canary Islands, Strait of Gibraltar, Swiss Alps, Iceland, Black Sea, and Red Sea. It encourages spreading awareness of Earth's beauty so future generations can appreciate and protect it.
The document discusses open-source and proprietary library catalog software. It defines open-source software and lists some examples of open-source library catalog software like Koha, Evergreen, phpMyLibrary, and OpenBiblio. The document notes that open-source software is free but requires technical expertise for support, while proprietary software has costs for licensing but includes training and support. When choosing, libraries should consider needs, available support resources, and total costs of ownership.
constellation energy Q1 2007 Earnings Presentation 2007 First Quarterfinance12
Constellation Energy reported strong earnings growth in Q1 2007 driven by solid Merchant performance. Adjusted EPS was $1.03, an increase of 69% over Q1 2006. Merchant earnings increased substantially due to higher power prices in the Mid-Atlantic region and lower costs for NewEnergy. BGE earnings were slightly lower than the prior year but within guidance. Constellation reaffirmed 2007 and 2008 EPS guidance and expects 10% EPS growth in 2009. The company is well positioned for future growth through its capital investment program and competitive strengths across power and gas.
The document provides details about the Top Thrill Dragster roller coaster located at Cedar Point amusement park in Ohio. It is the tallest and fastest roller coaster in the world, reaching speeds of 193 km/h within 4 seconds of leaving the station from a height of nearly 122 meters. The coaster cost $25 million to build and opened in 2003.
The document announces that Stephanie Streeter, former chairman, president and CEO of Banta Corporation, has been elected to Goodyear's board of directors. Streeter has over 20 years of experience in marketing and business leadership roles. She will receive standard compensation for non-employee directors. The document also notes amendments made to some of Goodyear's employee benefit plans and compensation agreements to comply with tax code requirements.
The document is a notice and proxy statement for Goodyear Tire & Rubber Company's 2003 Annual Meeting of Shareholders. The meeting will be held on May 7, 2003 at 10:00 AM at the Goodyear Theater in Akron, Ohio. Shareholders will vote on electing four directors, amending the Code of Regulations, ratifying the appointment of PricewaterhouseCoopers LLP as independent accountants, and considering a shareholder proposal. The proxy statement provides details on these voting items and includes information on the board of directors and executive compensation.
This document summarizes environmental data collected from 2001-2011 at a GLOBE site in Estonia located at 58.5205° N, 25.6266° E. Measurements included atmospheric temperature and pressure, hydrology, soil temperature, and plant phenology. Some key findings were very cold/warm winters in 2009/2010 and 2007/2008, and warmer summers in 2009 and 2008. Dissolved oxygen and pH in surface water were also measured from 2003-2006. The document also describes GLOBE activities in Estonia such as camps, workshops in other countries, and a 5th anniversary celebration in 2005.
This document discusses various instructional strategies to enhance student engagement based on research from multiple sources. It describes how boredom can lead to stress and misbehavior in students when their brains are not sufficiently stimulated. Several engagement strategies are presented, including using novelty, visuals, humor, music, role playing and connecting lessons to students' emotions. Graphic organizers, mind maps, and techniques like think-pair-share are recommended to appeal to different learning styles and improve retention of information. The goal is to actively involve students and stimulate their brains in multiple ways to maximize attention and long-term memory of classroom content.
Contending that Ohioans are not adequately protected from the risks of horizontal, hydrological fracturing - or "fracking" - for oil and gas, the Ohio Environmental Council is proposing a sweeping upgrade to state oil and gas laws. The proposed bill, called SAFER GAS (Safeguarding Appalachian Families with Environmental Regulation of Gas And Shale), shores up more than 30 gaps in Ohio law.
This document discusses vernal pools as important amphibian breeding habitat. It notes that vernal pools are seasonal forest depressions fed by surface water and groundwater. They provide habitat for many amphibian species but are disappearing. The document summarizes the habitat needs of various amphibian species that use vernal pools, including woodlands surrounding the pools, seasonal hydrology, an absence of fish, and leaf litter. It emphasizes that protecting existing vernal pool habitats and creating new habitats is important for reversing the decline of amphibian populations that rely on these ephemeral wetlands.
A Lake Erie Twofer: Tiny Plastic Particles and Toxic Algae Threaten Lake WatersOhio Environmental Council
A panel of experts discuss the impact of toxic algae and microbeads on the health and well-being of Lake Erie.
Presenters:
- Dr. Jeffery Reutter, Director Ohio Sea Grant College Program
- Dr. Sue Watson, Research Scientist, WHERD, Water Science and Technology, Environment Canada
- Andy McClure, Administrator, Collins Park Water Treatment, Toledo, OH
- Dr. Sheri Mason, Professor, Department of Chemistry and Biochemistry at SUNY Fredonia
This document provides a long list of websites and resources for global education projects and ideas. Some of the resources listed include websites for global networking like TakingItGlobal.org and IEARN.org, as well as resources on specific project ideas like Flat Stanley, Jason Science, and global issues documentary projects. The document encourages using these resources to identify issues, tell stories, determine ways to help, and create business plans to present solutions. It concludes by thanking the reader and providing contact information.
The document provides an agenda and materials for an event on air quality and health. The agenda includes sessions on how air quality impacts the environment, the federal government's role, and actions individuals can take to reduce pollution. The sessions will discuss how ozone pollution and particulate matter harm crops, forests, wildlife, and the climate. They will also suggest ways for individuals to help through reducing electricity use, transportation choices, advocacy, and more. Presenters will discuss these topics from the Ohio Environmental Council and American Lung Association.
wyeth UBS Global Life Sciences Conferencefinance12
Greg Norden, CFO of Wyeth, presented at the UBS Global Life Sciences Conference on September 25, 2007. He discussed Wyeth's strong financial performance in the second quarter and first half of 2007, with 10% revenue growth and earnings per share increases of 13-12%. Norden highlighted several of Wyeth's key marketed products that contributed significantly to revenue growth, including Enbrel, Prevnar, Effexor, and Nutritionals. He also provided an outlook for 2007 with raised EPS guidance and expectations for continued bottom line growth outpacing revenue growth.
wyeth Wyeth at Credit Suisse Healthcare Conferencefinance12
This document summarizes a presentation given by Joe Mahady from Wyeth Pharmaceuticals at a healthcare conference on November 13, 2007. It discusses Wyeth's financial performance for Q3 and the first nine months of 2007, with revenue and earnings per share up 9-14% and 7-10% respectively. It highlights several of Wyeth's key marketed products, including Enbrel, Effexor, Prevnar, and Protonix, which showed strong growth. It also outlines Wyeth's leadership positions in various therapeutic areas and the growth potential for products like Enbrel, Prevnar, and Zyvox.
johnson & johnson PDF Download Presentationfinance4
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered sales growth of 4.3% in 2008 and exceeded earnings guidance. All three business segments - pharmaceutical, medical devices & diagnostics, and consumer - experienced sales growth.
- The presentation identifies growth drivers and pipeline advancements across J&J's businesses. It also addresses challenges from the economic environment and strategies to manage pressures in 2009.
- Looking forward, J&J will focus on growing existing businesses, building new platforms, and participating in healthcare policy to position itself for long-term leadership in an evolving industry.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered strong financial results in 2008, meeting guidance targets for sales growth and adjusted earnings per share.
- The company's three business segments - pharmaceuticals, medical devices & diagnostics, and consumer - all experienced sales growth in 2008.
- J&J is advancing its pharmaceutical, medical device, and consumer product pipelines with numerous new product filings planned for 2009-2010.
- While macroeconomic uncertainties may impact 2009 performance, J&J is well positioned due to its diversified business portfolio and continued investment in R&D and new product development.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered sales growth of 4.3% in 2008 and exceeded earnings guidance despite challenges.
- Consumer and Medical Devices & Diagnostics saw sales growth while Pharmaceutical sales declined due to patent expirations.
- The company is focusing on new product launches, emerging markets, and cost reductions to address current economic pressures.
- J&J's strategic focus is on winning in healthcare through R&D, new growth platforms, and participation in public policy to shape the evolving healthcare environment.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered sales growth of 4.3% in 2008 and exceeded earnings guidance. All three business segments - pharmaceutical, medical devices & diagnostics, and consumer - experienced sales growth.
- The presentation identifies growth drivers and pipeline advancements across J&J's businesses. It also addresses challenges from the economic environment and strategies to manage pressures in 2009.
- Looking forward, J&J will focus on growing existing businesses, building new platforms, and participating in healthcare policy to "win in healthcare" over the long term.
This document summarizes Comcast's 4th quarter and full year 2008 results. In 2008, Comcast met or exceeded its financial goals and made solid progress on strategic initiatives to enhance growth and competitiveness. For the 4th quarter, cable revenue grew 7% year-over-year to $8.3 billion, while cable operating cash flow decreased 14% to $0.9 billion due to higher programming and marketing costs. For the full year, revenue grew 8% to $34.3 billion and operating cash flow increased 8.5% to $13.1 billion. Comcast will focus on profitable growth, improving returns, and free cash flow generation in 2009.
cardinal health Q3 2008 Earnings Presentationfinance2
The document summarizes Cardinal Health's Q3 FY2008 earnings call. It includes opening remarks from the CEO and CFO. The CFO provides an overview of Q3 financial results including revenue growth of 5% and EPS growth of 13%. Segment results are also summarized, with Healthcare Supply Chain Services facing challenges from repricings and controlled substance regulations while Medical Products and Technologies saw growth from acquisitions. Clinical Technologies and Services saw continued strong performance. Full year guidance targets the mid-point of $3.75-3.85 EPS, excluding a small dilution from a recent acquisition.
cardinal health 2008 Earnings Presentationfinance2
The document summarizes Cardinal Health's Q4 FY2008 earnings call with investors and analysts. It discusses financial results for Q4 and full year FY2008, with revenue growth of 3% and 5% respectively. It provides segment results for Healthcare Supply Chain Services and Clinical & Medical Products. The document also outlines financial goals and assumptions for FY2009, with total revenue growth forecast at 6-7% and non-GAAP EPS of $3.80-$3.95. Key priorities for FY2009 are also mentioned.
wyeth UBS Global Life Sciences Conferencefinance12
The document is a presentation from Mary Katherine Wold, Senior Vice President of Taxes and Treasury at UBS Global Life Sciences Conference on September 26, 2006. It discusses Wyeth's financial performance for the first half of 2006, with net revenue increasing 8% to $10 billion and net income increasing 15% to $1.94 billion. It also provides updates on several of Wyeth's key marketed products, including Enbrel, Effexor, Prevnar, Protonix, and Premarin.
cardinal health Q2 2008 Earnings Presentationfinance2
The document summarizes Cardinal Health's Q2 FY2008 earnings call. It provides an overview of the company's financial results for Q2, including revenue growth of 7% but flat operating earnings growth of 1%. It reviews results and highlights for each of the company's business segments. The document also discusses Cardinal Health's FY2008 financial targets, goals and outlook, noting lowered EPS guidance of $3.75-3.85 due to challenges in the pharmaceutical supply chain business.
SPX reported financial results for the third quarter of 2008. Revenue increased 29% to $1.51 billion due to a 20% increase from acquisitions and 6.5% organic growth. Adjusted earnings per share grew 19% to $1.66 compared to the prior year. For the full year, revenue is expected to increase 8-10% organically in the fourth quarter. Earnings per share for the fourth quarter are targeted to be between $1.90 and $2.00, representing 14-20% growth over the prior year.
wyeth J.P. Morgan 26th Annual Healthcare Conferencefinance12
This document summarizes a presentation given at the J.P. Morgan 26th Annual Healthcare Conference. It discusses Wyeth's financial performance in Q3 and the first nine months of 2007, with revenue and earnings growth across key franchises like Enbrel, Effexor, Prevnar, and Protonix. It also highlights Wyeth's approved, pending, and upcoming opportunities, including new data on drugs like Pristiq, Torisel, and expanded indications for Prevnar 13. Wyeth expects continued growth from these pharmaceutical products and advancing its oncology pipeline.
Boyuan Construction Investor PresentationTMX Equicom
The document provides an overview of Boyuan Construction Group, a construction company listed on the TSX Venture Exchange. It discusses Boyuan's markets in the Yangtze River Delta region and Sanya city of China, as well as its expansion to Shandong province. The presentation outlines Boyuan's financial performance, competitive advantages, growth strategies, management team, and sample projects. It also provides industry data on the growth and size of the Chinese construction market.
cardinal health Q1 2008 Earnings Presentationfinance2
This document summarizes Cardinal Health's Q1 FY2008 earnings call from November 5, 2007.
- Consolidated revenue grew 5% year-over-year to $21.973 billion, while non-GAAP operating earnings grew 8% to $512 million and non-GAAP diluted EPS grew 15% to $0.86.
- Healthcare Supply Chain Services pharmaceutical revenue grew 4% to $19.221 billion, while segment profit grew 6% to $305 million. Medical revenue grew 6% to $1.921 billion, while segment profit declined 10% to $58 million.
- Cardinal Health is reconfirming its non-GAAP EPS guidance range of $3
wyeth Cowen and Company Annual Health Care Conferencefinance12
Geno Germano, President of U.S. and General Manager of Wyeth Pharmaceuticals, presented at the Cowen Health Care Conference on March 13, 2007. He discussed Wyeth's strong financial growth in 2006, new commercial models being implemented, and upcoming FDA submissions including Pristiq for depression and menopausal symptoms. Germano emphasized building a diverse and stronger company through top line growth, cost management, and outpacing revenue growth with bottom line growth.
IAB Internet Advertising Revenue Reporttony anderson
IAB Internet Advertising
Revenue Report Social Media Metrics Definitions
Tony Anderson, Online Media Sales
Gen-Y Media Inc.
www.genymediainc.com tony@genymediainc.com
Online Ad Sales
Ad Serving, DoubleClick, DART DFP, adapt
This document summarizes Pfizer's fourth quarter 2007 earnings teleconference. It reports that Pfizer exceeded its 2007 revenue and EPS guidance. Key highlights included:
- Revenue increased 4% year-over-year in Q4 2007 and 1% for full year 2007. Adjusted diluted EPS increased 21% in Q4 2007 and 7% for full year.
- New products like Chantix, Lyrica and Sutent grew substantially and partially offset declines from products that lost exclusivity.
- 2008 guidance was increased, with revenue range increased and bottom end of EPS guidance also increased.
- Cost reduction initiatives continued to reduce expenses, with further savings expected in 2008.
- Yahoo reported Q3 2008 revenue of $1.786 billion, a 1% increase year-over-year. Revenue excluding traffic acquisition costs (Revenue ex-TAC) decreased 2% year-over-year to $1.325 billion.
- Operating cash flow (OCF) for Q3 2008 was $410 million, a 12% decrease year-over-year, and included $37 million in costs related to Microsoft proposals and other strategic initiatives.
- Free cash flow (FCF) for Q3 2008 was $231 million, a 52% FCF to OCF ratio, and included a one-time payment from AT&T in the prior quarter.
- Non-GAAP earnings
View Summary Manpower Inc. Withdraws Fourth Quarter 2008 Guidance 12/22/2008finance12
Manpower Inc. withdrew its fourth quarter 2008 guidance due to continued declines in the global labor markets and changes in foreign currencies. The company experienced a 20% revenue decline in the two months ended November 30, 2008 compared to the prior year. As a result of the weaker operating environment, Manpower Inc. will take restructuring charges related to employee severance and office closures in the fourth quarter. Despite the economic challenges, the company's liquidity and financial strength remains strong with $675 million in cash and $182 million in net debt as of the end of November.
The document is the 1999 annual report of Manpower Inc. It discusses the company's financial highlights for 1999, including increased systemwide sales, revenues, and operating margin compared to previous years. It summarizes the company's strategies to focus on providing workforce solutions, investing in technology, improving efficiency, and expanding in professional and specialty staffing. The report discusses how these strategies helped drive growth while improving profitability in 1999.
Manpower provided staffing solutions for a variety of clients around the world in 2000. Some key examples include:
1) Manpower Venezuela used a performance-based compensation model to win staffing contracts for three call centers in Venezuela.
2) In Australia, the Defense Force outsourced its military recruitment to Manpower due to their ability to provide a full-service solution.
3) In North Carolina, Manpower's workforce program helped IBM achieve significant contractor staffing cost savings.
This document highlights Manpower's global reach and ability to customize staffing solutions to meet the diverse needs of clients around the world.
The document is Manpower Inc.'s 2001 annual report. It summarizes that in 2001:
- Systemwide sales decreased 5.3% to $11.8 billion due to a weaker global economy and strengthening US dollar.
- Revenues decreased 3.3% and operating profit declined 23.6% as revenue growth slowed but investments continued.
- Earnings per share decreased 27% to $1.62 primarily due to currency exchange impacts. The company remained focused on providing skilled employees and workforce solutions to customers during economic uncertainty.
The document discusses Manpower's performance and strategies during a period of economic uncertainty in 2002. It summarizes that Manpower strengthened its financial position, improved efficiency, expanded services, and increased customer relationships despite challenging market conditions. Manpower emerged stronger and confident in its leadership position. The speed of work increased pressure on companies, but Manpower provided flexibility and quality service to help customers.
This document contains a long list of place names from around the world arranged in no clear order. The places span multiple continents and countries, including locations in France, Italy, Germany, Japan, Canada, Mexico, Argentina and many others.
The document is Manpower Inc.'s 2004 annual report. It discusses Manpower's 57-year history of providing temporary staffing solutions and how it has expanded its services over time. It also discusses how the world of work is constantly changing and how Manpower continues to adapt its solutions to help clients with their HR strategies and market competition. The report features perspectives from clients, including IBM's vice president of global talent discussing how IBM partners with Manpower for just-in-time talent management to source skills globally on demand.
This document is Manpower Inc.'s 2005 annual report. It summarizes the company's financial performance for 2005, noting revenues exceeded $16 billion, a 7.7% increase over 2004. Net income increased 8% to $260 million. It also discusses strategic moves taken in 2005 to expand operations in emerging markets like China and India. Finally, it describes the company's rebranding effort, launching a new logo and tagline - "What do you do?" - to reflect its expanded services beyond temporary staffing.
Manpower Inc. reported record financial results in 2006. Revenues increased 10.8% to $17.6 billion and net earnings increased 53% to $398 million. The company's stock price rose 61% in 2006, outperforming the broader market. Operating profit increased 24% to $532 million due to growth in business and effective cost management across regions. The company has transitioned to focus on providing a wider range of employment services beyond temporary staffing alone. The rebranding launched in 2006 aligned the company's image with this strategic transition and positioned Manpower for continued strong performance.
Manpower Inc. had record revenues and earnings in 2007. Revenues increased 17% to $20.5 billion while net earnings grew 22% to $484.7 million. The company has diversified its services over the past decade to include specialty services beyond temporary staffing, such as permanent recruitment and leadership development. This has improved profit margins and reduced sensitivity to economic cycles. Investments in new services like recruitment process outsourcing have positioned Manpower for continued growth.
The document is a Form 8-K filed by The Goodyear Tire & Rubber Company with the SEC on May 22, 2007. It announces that the company entered into an underwriting agreement to sell over 22 million shares of its common stock in a public offering at $33 per share, for total proceeds of over $750 million. The underwriters exercised their option to purchase additional shares. The company's general counsel issued a legality opinion on the shares offering. The proceeds will be used for general corporate purposes.
The Goodyear Tire & Rubber Company issued notices to partially redeem outstanding notes. It will redeem $140 million of its 9% Senior Notes due 2015 at 109% of par value, and $175 million of its 8.625% Senior Notes due 2011 at 108.625% of par value. Both redemptions will occur on June 29, 2007. Goodyear is using proceeds from a recent equity offering of common stock to fund the redemptions, as allowed under provisions permitting redemption of up to 35% of notes with equity offering proceeds.
Unlocking Your Dream Home Understanding Government Subsidies for House and Ho...Kathiriyasubsidyhouse
Purchasing a home is a significant milestone, but the financial commitment can be daunting. Thankfully, various government subsidies and schemes can ease the burden. In this blog post, we'll delve into the intricacies of the government subsidy for house, the benefits of a government subsidy on home loan, and the attractive housing loan interest subsidy offered by Kathiriya Subsidy House. Understanding these can help you make informed decisions and potentially save a substantial amount of money on your home purchase.
Typical Scams to Stay Away from When Buying Verified Binance AccountsAny kyc Account
In the world of cryptocurrency, having a verified Binance account can provide numerous benefits. However, with the growing demand for these accounts, the risk of encountering scams also increases. This presentation aims to educate you on the most common scams to avoid when buying verified Binance accounts and provide tips for safe transactions.
Building Trust Through Transparency Kissht's Commitment during Regulatory Cr...Kissht Reviews
Kissht, a leading India fintech company, has shown an unwavering commitment to these principles, particularly during periods of regulatory crackdowns. By prioritizing transparency and robust compliance measures, Kissht has not only built trust among its users but also established itself as a reliable and ethical player in the fintech industry.
Abortion pills in Muscat(+918133066128) Cytotec pills buy Omanmaishakhanam230
Abortion pills Kuwait☎️+918133066128☎️ Kuwait City Qatar- Doha Abortion Saudi Arabia [ Abortion pills) Jeddah/riaydh/dammam/+918133066128☎️] cytotec tablets uses abortion pills 💊💊 How effective is the abortion pill? 💊💊 +918133066128) "Abortion pills in Jeddah" how to get cytotec tablets in Riyadh " Abortion pills in dammam*💊💊 The abortion pill is very effective. If you’re taking mifepristone and misoprostol, it depends on how far along the pregnancy is, and how many doses of medicine you take:💊💊 +918133066128) how to buy cytotec pills
At 8 weeks pregnant or less, it works about 94-98% of the time. +918133066128[ 💊💊💊 At 8-9 weeks pregnant, it works about 94-96% of the time. +918133066128) At 9-10 weeks pregnant, it works about 91-93% of the time. +918133066128)💊💊 If you take an extra dose of misoprostol, it works about 99% of the time. At 10-11 weeks pregnant, it works about 87% of the time. +918133066128) If you take an extra dose of misoprostol, it works about 98% of the time. In general, taking both mifepristone and+918133066128 misoprostol works a bit better than taking misoprostol only. +918133066128 Taking misoprostol alone works to end the+918133066128 pregnancy about 85-95% of the time — depending on how far along the+918133066128 pregnancy is and how you take the medicine. +918133066128 The abortion pill usually works, but if it doesn’t, you can take more medicine or have an in-clinic abortion. +918133066128 When can I take the abortion pill?+918133066128 In general, you can have a medication abortion up to 77 days (11 weeks)+918133066128 after the first day of your last period. If it’s been 78 days or more since the first day of your last+918133066128 period, you can have an in-clinic abortion to end your pregnancy.+918133066128
Why do people choose the abortion pill? Which kind of abortion you choose all depends on your personal+918133066128 preference and situation. With+918133066128 medication+918133066128 abortion, some people like that you don’t need to have a procedure in a doctor’s office. You can have your medication abortion on your own+918133066128 schedule, at home or in another comfortable place that you choose.+918133066128 You get to decide who you want to be with during your abortion, or you can go it alone. Because+918133066128 medication abortion is similar to a miscarriage, many people feel like it’s more “natural” and less invasive. And some+918133066128 people may not have an in-clinic abortion provider close by, so abortion pills are more available to+918133066128 them. +918133066128 Your doctor, nurse, or health center staff can help you decide which kind of abortion is best for you. +918133066128 More questions from patients: Saudi Arabia+918133066128 CYTOTEC Misoprostol Tablets. Misoprostol is a medication that can prevent stomach ulcers if you also take NSAID medications. It reduces the amount of acid in your stomach, which protects your stomach lining. The brand name of this medication is Cytotec®
What is an E-commerce- digital marketingpdfPurna Rai
What is an E-commerce?
E-commerce refers to the buying and selling of goods and services over the Internet. In an e-commerce transaction, the exchange of products or services takes place electronically, often through online platforms or websites. E-commerce has become a major aspect of the modern economy, enabling businesses and consumers to conduct transactions without the need for physical presence. It has gained immense popularity over recent years, with more people turning to online shopping for its convenience and accessibility.
E-commerce platforms provide a virtual marketplace where sellers can showcase their products, and buyers can browse and purchase items with just a few clicks. This has opened up new opportunities for entrepreneurs and businesses of all sizes, allowing them to reach a larger customer base and operate globally. However, e-commerce also presents its own set of challenges, such as competition, security concerns, and effectively managing logistics and customer experience. It is important for e-commerce businesses to stay up-to-date with evolving technologies, consumer trends, and effective marketing strategies to remain successful in this ever-growing industry.
What are the Key Components and Features of E-commerce?
E-commerce has various forms, including business-to-consumer (B2C), business-to-business (B2B), consumer-to-consumer (C2C), and more. The growth of e-commerce has transformed the way businesses operate and how consumers shop, providing convenience, accessibility, and a global marketplace. Key components and features of e-commerce include:
Online Stores: Businesses set up digital storefronts or online stores where customers can browse, select, and purchase products or services. These stores can take various forms, including dedicated websites, marketplaces, or social media platforms.
Electronic Payments: E-commerce transactions involve electronic payment methods. Customers can use credit cards, digital wallets, online banking, or other electronic payment systems for making payments.
Digital Marketing: E-commerce relies heavily on digital marketing strategies to attract customers. This includes search engine optimization (SEO), social media marketing, email marketing, and other online advertising methods.
Product Catalogs: Online stores have digital catalogs that showcase their products or services. These catalogs provide detailed information, images, and specifications to help customers make informed purchasing decisions.
Shopping Carts: E-commerce platforms typically incorporate shopping carts that allow customers to add products to their virtual cart, review their selections, and proceed to checkout for payment.
Secure Transactions: Security is a critical aspect of e-commerce. Secure socket layer (SSL) encryption is commonly used to ensure the confidentiality and integrity of sensitive information, such as payment details.
@Call @Girls Chennai X000XX000X High Profile ( Sandhiya )
wyeth Citi Investment Research Global Healthcare Conference
1. 2008 Citi Investment Research
Global Healthcare Conference
Greg Norden
Senior Vice President and Chief
Financial Officer
May 21, 2008
2. Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-
looking statements based on current expectations of future events and are
subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. These risks
and uncertainties include risks associated with the inherent uncertainty of the
timing and success of product research, development and commercialization
(including with respect to the NDA filings for Wyeth’s pipeline products
referenced in this presentation), drug pricing and payment for Wyeth’s
products by government and third-party payers, manufacturing, data
generated on the safety and efficacy of Wyeth’s products, the impact of
competitive or generic products, trade buying patterns, global business
operations, product liability and other types of litigation, the impact of
legislation and regulatory compliance, intellectual property rights, strategic
relationships with third parties, environmental liabilities, and other risks and
uncertainties, including those detailed from time to time in Wyeth’s periodic
reports filed with the Securities and Exchange Commission, including Wyeth’s
current reports on Form 8-K, quarterly reports on Form 10-Q and annual
reports on Form 10-K, particularly the discussion in Wyeth’s annual report on
Form 10-K under the caption quot;Item 1A, Risk Factors.quot; Wyeth assumes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future developments or otherwise.
2
3. 2008 Guidance*
Pro Forma EPS $3.35 to $3.49 (-1% to -5%)
n
Revenue Comparable to 2007
n
Gross Margin 72% to 74%
n
SG&A Down 2% (Excluding Any Impact from Foreign
n
Exchange)
R&D Up Slightly
n
Tax Rate 29% to 31%
n
Taking Aggressive Measures to Mitigate the Impact of
the Loss of Protonix to the Extent Possible
* Excludes Certain Significant Items
3
4. Wyeth 1Q 2008: Solid Performance Despite Impact
from “At-Risk” Generic Protonix Launches
Net Revenue ($B) Operating Profit ($B) Earnings Per
Share*
+0%
+6%
$6 $2.0 $1.00
+7%
$5
$1.5
$4
$5.7B $1.8B $.94
$3 $1.0 $0.50
$5.4B $1.7B $.94
$2
$0.5
$1
$0 $0.0 $0.00
1Q07 1Q08 1Q07 1Q08 1Q07 1Q08
* As Adjusted, Before Certain Significant Items
4
5. Results by Division: 1Q 2008
Worldwide Net Revenue
Increased 6% to $5.7 Billion for
the 2008 First Quarter
10%*
Pharmaceuticals
6%*
$4,758.8M
Animal Health
$276.6M
0%*
Consumer
Healthcare
$675.2M
* Represents percentage increase in 2008 First Quarter Net Revenue compared with 2007 1Q
5
6. Key Product Performance: 1Q 2008
36%
22%
19%
15% 14%
$1,021M
$706M
$606M
(66)%
$411M
$342M
$159M
Represents 2008 First Quarter Net Revenue and percentage increase (decrease) compared with 2007
1Q; amounts presented for Enbrel represent Net Revenue outside the U.S. and Canada,
where Wyeth has exclusive rights
6
7. Wyeth Pharmaceutical Success Imperatives
Drive Growth in Products and Regions
1.
Successfully Introduce New Products
2.
Sharpen Focus - Manage Costs – Define Path
3.
7
8. Wyeth Pharmaceutical Success Imperatives
Drive Growth in Products and Regions
1.
Successfully Introduce New Products
2.
Sharpen Focus - Manage Costs – Define Path
3.
8
9. Focus On Growth Drivers:
Strong and Growing Product Lines
2007 Revenue: $2.4 Billion (+24%)
Expect Mid-Teens Growth in 2008
®
2007 Revenue: $2 Billion Int’l. (+36%)
International Revenue Expected to Exceed $2.5
Billion in 2008 … $3 Billion Target in 2010
2007 Revenue: $1.4 Billion (+20%)
Expect 2008 Growth to Be Similar to Last Year
9
10. Focus On Growth Drivers:
Strong Contributors to Revenue
2007 Revenue: $3.8 Billion (+2%)
Expect 2008 Sales to Be Comparable to 2007
2007 Revenue: $1.1 Billion (+17%)
Expect International Generic Competition and
Possible Generic Competition in the U.S.
2007 Revenue: $1.1 Billion (+0%)
Progress Continues in Clarifying the Benefit/Risk
Profile of Hormone Therapy
10
11. Focus On Growth Drivers:
Strong Contributors to Revenue
2007 Revenue: $705 Million (+7%)
2007 Revenue: $684 Million (+10%)
2007 Revenue: $1,042 Million (+11%)
11
12. Focus On Growth Drivers:
Other Solid Contributors to Revenue
Hemophilia Franchise Grew 16% in 2007
Franchise Is on Track to Reach $1B in 2009
2007 Revenue: $359 Million (+17%)
BMP-2
2007 Revenue: $365 Million (+8%)
12
13. Drive Growth in Regions
Wyeth’s Growing International Presence
Evolution of Sales
2000 2007
24%
31%
61%
Revenue 52%
10%
12%
5%
6%
$13.1B $22.5B
US EMEA/C APAC LA
13
14. Increasing Contribution & Accelerating Growth
In Emerging Markets for Pharma Industry
Turkey/MENA
Western Europe Japan ROW $13B
China
+16%
$31B
$58B
$167B
$14B
+11%
+5%
+6%
+26%
Select Mexico
Emerging Markets $7B
$62B +8%
India
+16%
North America $7B
$295B Korea +13%
Korea
+4%
$8B
$8B
+14% Brazil
+14% Russia
$8B
$5B
+10%
+19%
2007 Global Rx Market: $612B (+6%)
2007 IMS Health (Rx Market), Russia sales based on 3Q MAT 2007.
MENA Countries include: IMS data for Saudi Arabia, S. Africa, UAE, Kuwait. The value is under-represented given several
14
countries are not included in the audit.
15. One Example of Wyeth’s Expansion Into
Accelerated Growth Markets
Wyeth Nutritionals - Geographic Expansion in China
Before Expansion 2008 Coverage
180
45 COVERED
COVERED
CITIES
CITIES
Currently Covered City City Expansion
15
16. Wyeth Pharmaceutical Success Imperatives
Drive Growth in Products and Regions
1.
Successfully Introduce New Products
2.
Sharpen Focus - Manage Costs – Define Path
3.
16
17. Successfully Introduce New Products
Continued and Projected 2008 Launches
cSSSI and cIAI
Community Acquired Pneumonia
Renal Cell Carcinoma
Depression
Hemophilia A
Opioid Induced Constipation
Flea and Tick Protection for Dogs and
Flea Protection for Cats
17
19. Prevnar 13v – Expanding the Coverage
Infant Adult
• Provide Broadest • Provide First and Only
Coverage Available for the Conjugate Vaccine That Offers
Global Protection of Adults, >50, an Opportunity to
Children Against Prevent Pneumococcal
Opportunity
Pneumococcal Disease Pneumonia for the Rest of Their
Lives
•
• Phase 2 Proof of Concept Proof of Concept Achieved
Achieved
• Licensing Criteria Agreed Upon
• Licensing Criteria Agreed • Worldwide Phase 3 Studies
Upon
Status
Ongoing
• Worldwide Phase 3 Studies
• Submission Early 2010
Ongoing
• Submission Early 2009
Peak Sales > $3 Billion > $1.5 Billion
19
20. Bapineuzumab
Phase 3 for Alzheimer’s Disease
Four Studies in Over 4,000 Patients Are Beginning
n
Worldwide
First U.S. Patient Enrolled December 2007; International Studies to Initiate
May 2008
Co-Primary Efficacy Endpoints – Validated Cognitive
n
and Functional Scales
Other Cognitive, Functional, Behavioral, Biomarkers, Health Outcomes
Endpoints
Phase 2 Data Mid-2008
n
Top Line Press Release
Full Data at ICAD in July
20
21. Wyeth Pharmaceutical Success Imperatives
Drive Growth in Products and Regions
1.
Successfully Introduce New Products
2.
Sharpen Focus - Manage Costs – Define Path
3.
21
22. Project Impact: Focus and Sequence
2008 2009 2010+
Level I: Cost Reduction
• Reduce/Eliminate Costs
and Expense
Level II: Business ModelModel & Structure
Level II: Business & Structure Refinement
• Change How We Operate and Improve Performance
Within Current Business Model and Structure
Level III: Pharma Strategic Redesign
Level III: Pharma Strategic Direction
• Change Our Business/Operating Model for the
Future
22
23. Project Impact: Functional Teams
Manufacturing Site Network
n
and Supply Productivity and Performance
n
Process Excellence
n
Offshoring and Outsourcing
n
Research and
Site Network and Spend Optimization
n
Pre-Clinical
Operational Efficiencies (Grants, etc.)
n
Clinical, Medical and
Alternative Investment Model
n
Regulatory
Portfolio Optimization
n
Global/Regional/Local/Business Unit
n
Commercial
Affiliate Structure
n
Sales Operating Model
n
Spend Effectiveness
n
23
24. Project Impact: Cross-Functional Teams
Purchased goods
and Services
Support Function Models
n
Demand Management
n
Information Services
Vendor Consolidation
n
Goods and Services Pricing
n
Facilities/Real Estate Review
n
Infrastructure/
Support
Therapeutic/Disease Areas
n
Portfolio/Pipeline Mix
Strategic Direction n
Specialty/Primary Care Mix
n
24
25. Key Financial Metrics
Net Cash (Including Diet Drug Security Funds) = $2.8
n
Billion
Cash and Cash Equivalents at 3/31/08 = $14.5 Billion
Total Debt at 3/31/08 = $11.7 Billion
Uses of Cash
n
Mergers and Acquisitions/In-Licensing
Share Repurchases
Dividends
Repayment of Debt
25
26. Wyeth: Positioning Itself for Future Growth
Diversified by Business
n
Prescription, Consumer, Animal Health
Primary Product Engines Continue to Offer Growth Opportunities
n
Enbrel, Prevnar, Nutritionals
New Product Launches Contributing to Revenue Growth
n
Proven Capability in Three R&D Platforms and Proven Ability to
n
Successfully Commercialize
Biotech, Vaccine and Small Molecules
Pipeline Offers Range of Options Including Both Near-Term and
n
Blockbuster Candidates
Positioned to Take Advantage of Global Growth Opportunities
n
26